MAPT and Alzheimer disease: In fact, several HDAC6 inhibitors have been reported to increase axonal transport of mitochondria and neurotrophic factors in various disease cell models4,23–25 and Tubastatin A, ACY-1215, MPT0G211, and 5-Aroylindoles have been demonstrated to have therapeutic potential including reduction in tau pathology in animal models of AD and other tauopathies26–29.